RGT Executes Global Licence for Non-Core Cannabis Genetics

Summary by 6ix AI

Argent Biopharma Ltd has entered into a ten-year exclusive global licensing agreement with Thai Phytomed International Co., Ltd for four proprietary cannabis genotypes. Under this agreement, Thai Phytomed will have exclusive rights to commercialize the licensed genetics while Argent retains ownership of the underlying intellectual property. Argent will receive a royalty based on profits generated from the commercialization of these genetics, supporting its strategy to monetize non-core assets. This transaction allows Argent to focus on its pharmaceutical development while benefiting from potential future revenues from these licensed genetics.

Written by 6ix AI from the company’s filing. How 6ix writes summaries